Comparing Saruparib to placebo in men with metastatic prostate cancer receiving hormonal treatment
Official title: A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Run by AstraZeneca · NCT06120491 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether a new drug called Saruparib can help men with advanced prostate cancer feel better when combined with hormonal treatments compared to a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 130 Years |
| Sex | Men only |
| Enrollment | 1800 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 410 sites (Chandler, Arizona and 409 other locations) |
| Trial ID | NCT06120491 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men aged 18 and older with histologically confirmed metastatic castration-sensitive prostate adenocarcinoma.
✕Probably not a fit
Patients with small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to demonstrate the superiority of Saruparib (AZD5305) combined with physician's choice of new hormonal agents (NHA) compared to a placebo with NHA in men with metastatic castration-sensitive prostate cancer (mCSPC). Approximately 1800 adult participants will be randomized into two cohorts based on their homologous recombination repair mutation (HRRm) status. Participants will receive their assigned treatment and undergo regular tumor evaluations until disease progression or treatment cessation. An independent data monitoring committee will oversee the safety and tolerability of the treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve radiographic progression-free survival for men with metastatic castration-sensitive prostate cancer.
How similar studies have gone: Other studies have shown promising results with similar approaches in treating metastatic prostate cancer, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male ≥ 18 years of age. * Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible. * Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI. * Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and \< 4 months prior to randomisation. * ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation. * Provision of FFPE tumour tissue sample and blood sample (for ctDNA). * Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility. * Adequate organ and bone marrow function as described in study protocol. * Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention. * Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners. Exclusion Criteria: * Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone biopsy) is required. * Participants with any known predisposition to bleeding. * Any history of persisting (\> 2 weeks) severe cytopenia. * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA. * History of another primary malignancy, with exceptions. * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy. * Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention. * Cardiac criteria, including history of arrhythmia and cardiovascular disease. * Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions. * Prior treatment within 14 days with blood product support or growth factor support. * Participants who are unevaluable for both bone and soft tissue progression.
Where it's running
-
Research Site
New Haven, Connecticut, United States Recruiting -
Research Site
Durham, North Carolina, United States Recruiting -
Research Site
Providence, Rhode Island, United States Recruiting -
Research Site
Myrtle Beach, South Carolina, United States Recruiting -
Research Site
San Antonio, Texas, United States Recruiting -
Research Site
Salt Lake City, Utah, United States Recruiting
Show 44 more locations
-
Research Site
Chermside, Australia Recruiting -
Research Site
Melbourne, Australia Recruiting -
Research Site
South Brisbane, Australia Recruiting -
Research Site
Krems, Austria Recruiting -
Research Site
Linz, Austria Recruiting -
Research Site
Vienna, Austria Recruiting -
Research Site
Vienna, Austria Recruiting -
Research Site
Calgary, Alberta, Canada Recruiting -
Research Site
Calgary, Alberta, Canada Recruiting -
Research Site
Abbotsford British Columbia, British Columbia, Canada Recruiting -
Research Site
Abbotsford British Columbia, British Columbia, Canada Recruiting -
Research Site
Kelowna, British Columbia, Canada Recruiting -
Research Site
Vancouver, British Columbia, Canada Recruiting -
Research Site
Kingston, Ontario, Canada Recruiting -
Research Site
Mississauga, Ontario, Canada Recruiting -
Research Site
Newmarket, Ontario, Canada Recruiting -
Research Site
Ottawa, Ontario, Canada Recruiting -
Research Site
Toronto, Ontario, Canada Recruiting -
Research Site
Toronto, Ontario, Canada Recruiting -
Research Site
Chicoutimi, Quebec, Canada Recruiting -
Research Site
Greenfield Park, Quebec, Canada Recruiting -
Research Site
Montreal, Quebec, Canada Recruiting -
Research Site
Montreal, Quebec, Canada Recruiting -
Research Site
Montreal, Quebec, Canada Recruiting -
Research Site
Québec, Quebec, Canada Recruiting -
Research Site
Saskatoon, Saskatchewan, Canada Recruiting -
Research Site
Bordeaux, France Recruiting -
Research Site
Clermont-Ferrand, France Recruiting -
Research Site
Lyon, France Recruiting -
Research Site
Montpellier, France Recruiting -
Research Site
Nice, France Recruiting -
Research Site
Paris, France Recruiting -
Research Site
Poitiers, France Recruiting -
Research Site
Hamburg, Germany Recruiting -
Research Site
Heidelberg, Germany Recruiting -
Research Site
Münster, Germany Recruiting -
Research Site
Nürtingen, Germany Recruiting -
Research Site
Tübingen, Germany Recruiting -
Research Site
Milan, Italy Recruiting -
Research Site
Rozzano, Italy Recruiting -
Research Site
George Town, Malaysia Recruiting -
Research Site
Johor Bahru, Malaysia Recruiting -
Research Site
Kota Kinabalu, Malaysia Recruiting -
Research Site
Kuala Lumpur, Malaysia Recruiting
+360 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Kim Nguyen Chi, MD — BC Cancer, Canada
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing a new injection for men with advanced prostate cancer
This study is testing a new injection for men with advanced prostate cancer to see how well it works and how safe it is.
-
Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve
This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.
-
Estrogen-Plus-ARSI for Hormone-Sensitive Metastatic Prostate Cancer
This phase 2 study tests whether adding transdermal estrogen to an androgen receptor signaling inhibitor improves quality of life for adults with newly diagnosed or recurrent metastatic hormone sensitive prostate cancer.
-
PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer
This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.
-
Recurrence-directed therapy with or without 12 months of androgen-deprivation (ELIGARD) for radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer
This will test whether adding 12 months of ELIGARD® (androgen-deprivation therapy) to recurrence-directed radiotherapy helps men with radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer stay progression-free longer.
-
Evaluating the addition of metformin and turmeric for prostate cancer treatment
This study is testing if adding metformin and turmeric to standard prostate cancer treatment helps men feel better and manage their cancer more effectively.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.